AR114732A1 - Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco - Google Patents

Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco

Info

Publication number
AR114732A1
AR114732A1 ARP190102617A ARP190102617A AR114732A1 AR 114732 A1 AR114732 A1 AR 114732A1 AR P190102617 A ARP190102617 A AR P190102617A AR P190102617 A ARP190102617 A AR P190102617A AR 114732 A1 AR114732 A1 AR 114732A1
Authority
AR
Argentina
Prior art keywords
trifluoromethyl
inhibitor
formation
cathepsin
drug antibodies
Prior art date
Application number
ARP190102617A
Other languages
English (en)
Inventor
De Almeida Bessa Juliana Mattos
Syed Sohail Ahmed
Young Marianne Manchester
Fabrice Alain Andr Kolb
Christian Klein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR114732A1 publication Critical patent/AR114732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente se refiere en particular a un inhibidor de catepsina S para la utilización en un método para reducir o impedir la formación de anticuerpos antifármaco (ADA) contra un agente terapéutico en un sujeto que está recibiendo un tratamiento con dicho agente terapéutico. Reivindicación 20: Inhibidor de catepsina S para la utilización, un método o un kit según cualquiera de las reivindicaciones 1 a 19, en el que el inhibidor de catepsina S es: (1-ciano-ciclopropil)-amida del ácido (2S,4R)-4-[4-(1-metil-1H-pirazol-4-il)-2-trifluorometil-bencenosulfonil]-1-(1-trifluorometil-ciclopropanocarbonil)-pirrolidín-2-carboxílico, o (1-ciano-ciclopropil)-amida del ácido (2S,4R)-4-[4-(5-metil-tetrazol-2-il)-2-trifluorometil-bencenosulfonil]-1-(1-trifluorometil-ciclopropanocarbonil)-pirrolidín-2-carboxílico; o una sal farmacéuticamente aceptable del mismo.
ARP190102617A 2018-09-18 2019-09-17 Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco AR114732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18195251 2018-09-18

Publications (1)

Publication Number Publication Date
AR114732A1 true AR114732A1 (es) 2020-10-07

Family

ID=63787710

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102617A AR114732A1 (es) 2018-09-18 2019-09-17 Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco

Country Status (15)

Country Link
US (1) US20210315863A1 (es)
EP (1) EP3852880A1 (es)
JP (1) JP7438198B2 (es)
KR (1) KR20210061344A (es)
CN (1) CN112839716A (es)
AR (1) AR114732A1 (es)
AU (1) AU2019344567A1 (es)
CA (1) CA3112032A1 (es)
CR (1) CR20210143A (es)
IL (1) IL281444A (es)
MA (1) MA53635A (es)
MX (1) MX2021003127A (es)
SG (1) SG11202102471XA (es)
TW (1) TW202023542A (es)
WO (1) WO2020058297A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573528B (zh) * 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
US20210332122A1 (en) * 2020-04-17 2021-10-28 Cedars-Sinai Medical Center Dysregulation of covid-19 receptor associated with ibd
WO2023245008A1 (en) * 2022-06-13 2023-12-21 Genentech, Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
AU2007246921A1 (en) 2006-04-10 2007-11-15 Fusion Antibodies Limited Therapy targeting Cathepsin S
ES2695047T3 (es) 2007-04-03 2018-12-28 Amgen Research (Munich) Gmbh Dominio de unión específico entre especies
UA106748C2 (uk) * 2009-04-20 2014-10-10 Ф. Хоффманн-Ля Рош Аг Похідні проліну як інгібітори катепсину
JP5878182B2 (ja) 2011-02-10 2016-03-08 ロシュ グリクアート アーゲー ミュータントインターロイキン−２ポリペプチド
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN104114549A (zh) * 2012-02-17 2014-10-22 霍夫曼-拉罗奇有限公司 新型吡咯烷衍生物
CR20180171A (es) 2015-10-07 2018-05-03 Hoffmann La Roche Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
CN108290954B (zh) * 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
KR20180111862A (ko) 2016-02-26 2018-10-11 에프. 호프만-라 로슈 아게 신규 피롤리딘 유도체
KR20200084006A (ko) 2017-11-01 2020-07-09 에프. 호프만-라 로슈 아게 표적화된 ox40 작용제를 사용하는 병용 요법

Also Published As

Publication number Publication date
SG11202102471XA (en) 2021-04-29
JP7438198B2 (ja) 2024-02-26
WO2020058297A1 (en) 2020-03-26
TW202023542A (zh) 2020-07-01
MX2021003127A (es) 2021-05-14
JP2022501356A (ja) 2022-01-06
EP3852880A1 (en) 2021-07-28
CA3112032A1 (en) 2020-03-26
CN112839716A (zh) 2021-05-25
KR20210061344A (ko) 2021-05-27
IL281444A (en) 2021-04-29
AU2019344567A1 (en) 2021-03-25
US20210315863A1 (en) 2021-10-14
CR20210143A (es) 2021-04-21
MA53635A (fr) 2022-04-13

Similar Documents

Publication Publication Date Title
AR114732A1 (es) Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
PE20161432A1 (es) Compuestos y composiciones para inducir condrogenesis
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
UY38351A (es) Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
RU2008120019A (ru) Средство для лечения кардиопатии
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
MX2021000778A (es) Metodos de tratamiento y prevencion de la enfermedad de alzheimer.
PE20190972A1 (es) Combinacion de agonistas de fxr
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2021013491A (es) Nuevas endolisinas de gardnerella y usos de las mismas.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
PH12020551772A1 (en) Oxo-substituted compound
AR127533A1 (es) INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ

Legal Events

Date Code Title Description
FB Suspension of granting procedure